Background: Pulmonary arterial hypertension (PAH) is often overlooked in systemic lupus erythematosus (SLE) patients. However, the association between SLE and PAH is gaining attention due to unique mechanisms and treatment responses.
Objectives: This study aims to categorise SLE-PAH patients by autoantibody profiles and evaluate long-term outcomes, including mortality and changes in PAH over 12 months.
Method: A hospital-based investigation included SLE patients diagnosed with PAH. We analysed mortality, PAH resolution, increases in anti-PAH therapy, and follow-up right ventricular systolic pressure (RVSP) over 12 months. K-means cluster analysis was used for clustering, with regression analyses predicting mortality.
Result: Analysing 111 SLE PAH patients revealed three clusters: Cluster 1 (CL1)-Sm-RNP positive (n=48), Cluster 2 (CL2)-no specific autoantibodies (n=36), and Cluster 3 (CL3)-multiple autoantibody positivity (n=27) (Smith, Sm-RNP, nucleosome, histone). Nephritis was significant in CL3 with multiple antibody positivity compared to CL1 and CL2 (p=0.01). CL1 showed a higher baseline mean RVSP (64.5 ± 19.1 (CL1) vs 57.5 ± 12.6 (CL2) vs 50.9 ± 12, p=0.002) and more frequent use of dual anti-PAH therapy (p=0.000). CL2, without any specific antibody, had an earlier onset of PAH (p=0.04). Significant improvement in PAH after withdrawing anti-PAH medication was noted in Cluster 3 (p=0.00). Regression analysis showed that aggressive anti-PAH therapy lowers PAH-related mortality (p=0.01), while nephritis (p=0.012) and positive dsDNA (p=0.009) correlate with higher mortality.
Conclusion: This study is the first to analyse SLE-PAH through cluster-based methods. Sm-RNP antibodies indicate more severe disease needing dual therapy, while multiple positive antibodies suggest a better prognosis, with most patients achieving PAH resolution.
背景:肺动脉高压(PAH)在系统性红斑狼疮(SLE)患者中经常被忽视。然而,SLE和PAH之间的关联由于其独特的机制和治疗反应而受到关注。目的:本研究旨在通过自身抗体谱对SLE-PAH患者进行分类,并评估长期预后,包括死亡率和PAH在12个月内的变化。方法:一项以医院为基础的调查,包括诊断为PAH的SLE患者。我们分析了死亡率、PAH消退、抗PAH治疗的增加以及随访12个月的右心室收缩压(RVSP)。聚类采用k均值聚类分析,回归分析预测死亡率。结果:分析111例SLE PAH患者,发现3组:第1组(CL1)-Sm-RNP阳性(n=48),第2组(CL2)-无特异性自身抗体(n=36),第3组(CL3)-多重自身抗体阳性(n=27) (Smith, Sm-RNP,核小体,组蛋白)。多抗体阳性的CL3组肾炎发生率明显高于CL1和CL2组(p=0.01)。CL1显示更高的基线平均RVSP(64.5±19.1 (CL1) vs 57.5±12.6 (CL2) vs 50.9±12,p=0.002)和更频繁地使用双重抗pah治疗(p=0.000)。无特异性抗体的CL2更早发生PAH (p=0.04)。第3组患者在停用抗PAH药物后PAH明显改善(p=0.00)。回归分析显示,积极的抗pah治疗降低了pah相关的死亡率(p=0.01),而肾炎(p=0.012)和dsDNA阳性(p=0.009)与更高的死亡率相关。结论:本研究首次采用基于聚类的方法对sle1 - pah进行分析。Sm-RNP抗体提示病情更严重,需要双重治疗,而多种抗体阳性提示预后更好,大多数患者获得PAH消退。
{"title":"The Long-Term Outcomes of Pulmonary Hypertension in Systemic Lupus Erythematosus (SLE-PAH) Vary Among Different Autoantibody-Based Clusters: An Observational, Longitudinal Study Conducted at a Single Centre in India.","authors":"Ritasman Baisya, Yerram Keerthi Vardhan, Murthy Gsr, Yerram Vivek Vardhan, Liza Rajasekhar","doi":"10.31138/mjr.060425.acl","DOIUrl":"10.31138/mjr.060425.acl","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary arterial hypertension (PAH) is often overlooked in systemic lupus erythematosus (SLE) patients. However, the association between SLE and PAH is gaining attention due to unique mechanisms and treatment responses.</p><p><strong>Objectives: </strong>This study aims to categorise SLE-PAH patients by autoantibody profiles and evaluate long-term outcomes, including mortality and changes in PAH over 12 months.</p><p><strong>Method: </strong>A hospital-based investigation included SLE patients diagnosed with PAH. We analysed mortality, PAH resolution, increases in anti-PAH therapy, and follow-up right ventricular systolic pressure (RVSP) over 12 months. K-means cluster analysis was used for clustering, with regression analyses predicting mortality.</p><p><strong>Result: </strong>Analysing 111 SLE PAH patients revealed three clusters: Cluster 1 (CL1)-Sm-RNP positive (n=48), Cluster 2 (CL2)-no specific autoantibodies (n=36), and Cluster 3 (CL3)-multiple autoantibody positivity (n=27) (Smith, Sm-RNP, nucleosome, histone). Nephritis was significant in CL3 with multiple antibody positivity compared to CL1 and CL2 (p=0.01). CL1 showed a higher baseline mean RVSP (64.5 ± 19.1 (CL1) vs 57.5 ± 12.6 (CL2) vs 50.9 ± 12, p=0.002) and more frequent use of dual anti-PAH therapy (p=0.000). CL2, without any specific antibody, had an earlier onset of PAH (p=0.04). Significant improvement in PAH after withdrawing anti-PAH medication was noted in Cluster 3 (p=0.00). Regression analysis showed that aggressive anti-PAH therapy lowers PAH-related mortality (p=0.01), while nephritis (p=0.012) and positive dsDNA (p=0.009) correlate with higher mortality.</p><p><strong>Conclusion: </strong>This study is the first to analyse SLE-PAH through cluster-based methods. Sm-RNP antibodies indicate more severe disease needing dual therapy, while multiple positive antibodies suggest a better prognosis, with most patients achieving PAH resolution.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 4","pages":"594-599"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-26eCollection Date: 2025-12-01DOI: 10.31138/mjr.080325.tav
Aymane Bennani, El Khalil Benmansour, Khalid Serraj
Objective: Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis.
Methods: We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I2 statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970.
Results: Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15).
Conclusion: Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.
目的:本研究旨在通过系统回顾和荟萃分析,评估抗肿瘤坏死因子英夫利昔单抗(IFX)治疗严重和/或难治性血管表现的behet病(BD)患者的有效性。方法:检索PubMed、Scopus、Web of Science和Cochrane Library数据库,寻找符合条件的研究。对比例进行meta分析。采用Cochrane’s Q检验和I2统计量评估异质性。所有统计分析均采用随机效应模型,采用R软件(版本4.4.2),PROSPERO注册号CRD42025640970。结果:在最初确定的2127个结果中,11项研究共284例患者被纳入最终分析。英夫利昔单抗诱导78.17%的患者血管完全缓解(95% CI 63.11-90.61)。肺动脉动脉瘤和静脉血栓事件亚组缓解率分别为99.13% (95% CI 86.21-100)和86.48% (95% CI 71.81-97.15)。结论:我们的系统评价和荟萃分析支持英夫利昔单抗在严重和/或难治性血管性behet病患者中的应用,特别是在涉及肺动脉动脉瘤的病例中。
{"title":"The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis.","authors":"Aymane Bennani, El Khalil Benmansour, Khalid Serraj","doi":"10.31138/mjr.080325.tav","DOIUrl":"10.31138/mjr.080325.tav","url":null,"abstract":"<p><strong>Objective: </strong>Our study aims to evaluate the effectiveness of anti-tumour-necrosis-factor Infliximab (IFX) in treating patients with severe and/or refractory vascular manifestations of Behçet's disease (BD) through a systematic review and meta-analysis.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Web of Science, and Cochrane Library databases for eligible studies. Meta-analysis of proportions was performed. Heterogeneity was assessed with Cochrane's Q test and I<sup>2</sup> statistics. Random effects models were used for all statistical analyses which were conducted on R software (version 4.4.2), PROSPERO registry number CRD42025640970<i>.</i></p><p><strong>Results: </strong>Of the 2127 results initially identified, 11 studies with a total of 284 patients were included in the final analysis. Infliximab induced complete vascular response in 78.17% of patients (95% CI 63.11-90.61). The remission rates in the subgroups of patients with pulmonary artery aneurysm and the venous thrombosis events were respectively 99.13% (95% CI 86.21-100) and 86.48 % (95% CI 71.81-97.15).</p><p><strong>Conclusion: </strong>Our systematic review and meta-analysis support the use of infliximab in patients with severe and/or refractory vascular Behçet's disease, particularly in cases involving pulmonary artery aneurysms.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 4","pages":"539-546"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-20eCollection Date: 2025-09-01DOI: 10.31138/mjr.220125.era
Cristine Kuzhuppilly Arcilla, Tomas Marek, Gurjit Kaeley
Vasculitides encompass a group of inflammatory diseases that affect blood vessels, leading to vessel wall thickening, ischemia, and potential organ damage. While rare, the prevalence of vasculitis has increased in recent years. Its presentation often mimics infectious and paraneoplastic diseases, requiring the identification of risk factors and individualised diagnostic workup. Delayed or inaccurate diagnosis of vasculitis can result in significant morbidity, vascular complications, and death since specific therapy depends on underlying aetiology and pathology. This case series highlights three patients presenting with mycotic pseudoaneurysm, infectious occlusive iliac thrombus relative to a chronic state of immunosuppression, infections, and malignancy associated with Crohn-related fistulas, Campylobacter fetus bacteraemia, and paraneoplastic aetiologies, resulting in poor patient outcomes. It is crucial to distinguish primary vasculitis from secondary aetiologies and mimickers, as misdiagnosis can lead to unnecessary, potentially harmful treatments and delay in surgical interventions if indicated.
{"title":"The Great Vasculitis Pretenders: Mycotic Pseudoaneurysm, Aortitis with Occlusive Iliac Thrombus, and Paraneoplastic Aortitis. A Case-Based Review.","authors":"Cristine Kuzhuppilly Arcilla, Tomas Marek, Gurjit Kaeley","doi":"10.31138/mjr.220125.era","DOIUrl":"10.31138/mjr.220125.era","url":null,"abstract":"<p><p>Vasculitides encompass a group of inflammatory diseases that affect blood vessels, leading to vessel wall thickening, ischemia, and potential organ damage. While rare, the prevalence of vasculitis has increased in recent years. Its presentation often mimics infectious and paraneoplastic diseases, requiring the identification of risk factors and individualised diagnostic workup. Delayed or inaccurate diagnosis of vasculitis can result in significant morbidity, vascular complications, and death since specific therapy depends on underlying aetiology and pathology. This case series highlights three patients presenting with mycotic pseudoaneurysm, infectious occlusive iliac thrombus relative to a chronic state of immunosuppression, infections, and malignancy associated with Crohn-related fistulas, <i>Campylobacter fetus</i> bacteraemia, and paraneoplastic aetiologies, resulting in poor patient outcomes. It is crucial to distinguish primary vasculitis from secondary aetiologies and mimickers, as misdiagnosis can lead to unnecessary, potentially harmful treatments and delay in surgical interventions if indicated.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"488-496"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-20eCollection Date: 2025-09-01DOI: 10.31138/mjr.261224.hfm
Burak Tayyip Dede, Didem Erdem Gürsoy, Muhammed Oğuz, Bülent Alyanak, Fatih Bağcıer
Background: The aim of this study was to evaluate the quality, completeness, accuracy, and readability of Large Language Models (LLM) responses to 25 popular questions about Familial Mediterranean Fever (FMF).
Methods: The readability of the responses of LLMs (ChatGPT-4, Copilot, Gemini) was assessed by Flesch Reading Ease Score (FRES) and Flesch-Kincaid Grade (FKG). The Ensuring Quality Information for Patients (EQIP) tool was used to assess the quality. To assess the completeness and accuracy of responses, 3-point and 5-point Likert scales were used, respectively.
Results: The mean FRES scores of LLMs ranged between 29.80 and 35.66. The FKG scores ranged between 12.36 and 13.72. The mean accuracy scores of LLMs ranged between 4.88 and 4.96. No significant difference was found between the LLM groups regarding accuracy and readability scores (p>0.05). The mean completeness scores of LLMs ranged between 2.36 and 2.84. ChatGPT-4 was the leading LLM in completeness scores according to the Likert scale, and the difference between LLM groups was statistically significant (p=0.006). Gemini performed better in the quality analysis with the EQIP tool, and there was a statistically significant difference between the LLM groups (p<0.001).
Conclusion: In this study, LLMs performed acceptably in accuracy and completeness. However, there are serious concerns about their readability and quality. To improve health information, LLM developers should include more diverse data sources in the training sets of the models. Moreover, the ability of LLMs to provide readability features that are adaptable to the level of education could be an important innovation in this field.
{"title":"What Large Language Models offer about Familial Mediterranean Fever: An Analysis of Quality, Readability, Completeness, and Accuracy.","authors":"Burak Tayyip Dede, Didem Erdem Gürsoy, Muhammed Oğuz, Bülent Alyanak, Fatih Bağcıer","doi":"10.31138/mjr.261224.hfm","DOIUrl":"10.31138/mjr.261224.hfm","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the quality, completeness, accuracy, and readability of Large Language Models (LLM) responses to 25 popular questions about Familial Mediterranean Fever (FMF).</p><p><strong>Methods: </strong>The readability of the responses of LLMs (ChatGPT-4, Copilot, Gemini) was assessed by Flesch Reading Ease Score (FRES) and Flesch-Kincaid Grade (FKG). The Ensuring Quality Information for Patients (EQIP) tool was used to assess the quality. To assess the completeness and accuracy of responses, 3-point and 5-point Likert scales were used, respectively.</p><p><strong>Results: </strong>The mean FRES scores of LLMs ranged between 29.80 and 35.66. The FKG scores ranged between 12.36 and 13.72. The mean accuracy scores of LLMs ranged between 4.88 and 4.96. No significant difference was found between the LLM groups regarding accuracy and readability scores (p>0.05). The mean completeness scores of LLMs ranged between 2.36 and 2.84. ChatGPT-4 was the leading LLM in completeness scores according to the Likert scale, and the difference between LLM groups was statistically significant (p=0.006). Gemini performed better in the quality analysis with the EQIP tool, and there was a statistically significant difference between the LLM groups (p<0.001).</p><p><strong>Conclusion: </strong>In this study, LLMs performed acceptably in accuracy and completeness. However, there are serious concerns about their readability and quality. To improve health information, LLM developers should include more diverse data sources in the training sets of the models. Moreover, the ability of LLMs to provide readability features that are adaptable to the level of education could be an important innovation in this field.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"410-416"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Indirect immunofluorescence (IIF) is a useful diagnostic modality for anti-neutrophilic cytoplasmic antibody (ANCA) detection in ANCA associated with vasculitis and diseases beyond vasculitis. As per latest guidelines, the IIF has been replaced by enzyme-linked immunosorbent assay (ELISA) as first line of screening for ANCA. The study intends to evaluate the performance of IIF and ELISA for ANCA testing and the impact of antinuclear antibody (ANA) positivity on ANCA reporting across these platforms.
Methods: A total of 70 samples, 53 ANA positive and 17 ANA negative, were included in the study. They were tested for ANCA across three different platforms based on IIF and ELISA. An attempt was also made to identify if presence and pattern of ANA affected ANCA reporting across any particular platform.
Results: The impact of ANA positivity on ANCA reporting was done using logistic regression analysis. An evaluation of the sensitivity and specificity of each ANCA testing platform was done considering ELISA as the reference method. Subgroup analyses were conducted on the basis of ANA patterns to further know their impact on the specificity and sensitivity of ANCA tests. The use of a 3-biochip combination for ANCA reporting by IIF resulted in a significant reduction of false positive ANCA due to ANA when a combination of ethanol and formalin fixed granulocytes were used.
Conclusion: There are notable differences in ANCA diagnostics between IIF based on ethanol fixed granulocytes alone and combination of three biochip. However, the addition of Proteinase 3/myeloperoxidase (PR3/MPO) dots to the 3-chip combination did not offer any added advantage.
{"title":"Diagnostic Performance of ANCA Testing Across Three Platforms with and without Coexisting ANA Positivity: Experience from a Tertiary Healthcare Centre in India.","authors":"Neha Rai, Shamshad Ahmad, Saurabh Karmakar, Divendu Bhushan, Pragya Kumar, Ayan Banerjee, Mukunda Kumar, Akash Bansal, Anurag Kumar, Rajiv Ranjan Sinha, Mala Mahto","doi":"10.31138/mjr.130225.eft","DOIUrl":"10.31138/mjr.130225.eft","url":null,"abstract":"<p><strong>Background: </strong>Indirect immunofluorescence (IIF) is a useful diagnostic modality for anti-neutrophilic cytoplasmic antibody (ANCA) detection in ANCA associated with vasculitis and diseases beyond vasculitis. As per latest guidelines, the IIF has been replaced by enzyme-linked immunosorbent assay (ELISA) as first line of screening for ANCA. The study intends to evaluate the performance of IIF and ELISA for ANCA testing and the impact of antinuclear antibody (ANA) positivity on ANCA reporting across these platforms.</p><p><strong>Methods: </strong>A total of 70 samples, 53 ANA positive and 17 ANA negative, were included in the study. They were tested for ANCA across three different platforms based on IIF and ELISA. An attempt was also made to identify if presence and pattern of ANA affected ANCA reporting across any particular platform.</p><p><strong>Results: </strong>The impact of ANA positivity on ANCA reporting was done using logistic regression analysis. An evaluation of the sensitivity and specificity of each ANCA testing platform was done considering ELISA as the reference method. Subgroup analyses were conducted on the basis of ANA patterns to further know their impact on the specificity and sensitivity of ANCA tests. The use of a 3-biochip combination for ANCA reporting by IIF resulted in a significant reduction of false positive ANCA due to ANA when a combination of ethanol and formalin fixed granulocytes were used.</p><p><strong>Conclusion: </strong>There are notable differences in ANCA diagnostics between IIF based on ethanol fixed granulocytes alone and combination of three biochip. However, the addition of Proteinase 3/myeloperoxidase (PR3/MPO) dots to the 3-chip combination did not offer any added advantage.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 4","pages":"584-593"},"PeriodicalIF":0.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-18eCollection Date: 2025-09-01DOI: 10.31138/mjr.211224.alf
Rajaie Namas, Sarah Al Qassimi, Jawahir Alameri, Samar Al Emadi, Nelly Ziade, Ahlam Almarzooqi, Farida Al Balushi, Mohammed A Omair, Taha Qardaghi, Yasameen Abbas Humadi, Mohamed Alawlaqi, Hanan Al Rayes, Saadeya Naji, Fatima Haji, Fajer Altamimi, Mansour Alazmi, Hani Shatnawi, Waleed Hafiz, Deena Ahmed, Mariam Almansoori, Jamal Al Saleh, Hazem Rifaai, Mahdi Abusalameh, Zaki Abou Zahr, Hiba Khogali, Sehriban Diab, Maha Anbar, Adeeba Al Herz, Amal Elganzoury, Shaima Ewila, Basant Elnady, Wafa Madanat, Imad Uthman, Asia Mubashir, Mohamed Elarabi, Suzan Attar
Background: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are significant causes of morbidity and mortality in systemic sclerosis (SSc). Our objective was to determine screening practices for ILD and PAH in patients with SSc among rheumatologists in the Middle East and North Africa (MENA) region.
Methods: An online questionnaire was distributed to rheumatologists across the MENA region. Participants were asked to estimate the proportion of SSc patients in their practice, indicate whether they screen for ILD and PAH, and specify how often they utilise screening modalities, including chest X-ray (CXR), high-resolution CT (HRCT), pulmonary function tests (PFTs), echocardiograms (ECHO), and the use of the DETECT algorithm. Data were analysed using descriptive statistics, with p-values ≤0.05 regarded as statistically significant.
Results: 394 respondents completed the questionnaire from 17 MENA countries. 389 (98.73%) reported screening for ILD, and 369 (93.65%) screened for PAH. 270 respondents performed screening at the time of SSc diagnosis (68.53%). Screening approaches for ILD included CXR (211, 53.55%), HRCT (321, 81.47%), and PFTs (299, 75.89%), while PAH screening included ECHO (346, 87.82%), and the DETECT algorithm (26.14%). Statistical differences were observed in the average number of SSc patients seen per year (p=0.0008), gender of respondents (p=0.02), current age (p=0.02), background training (p<0.00001), use of ECHO as PAH screening (p=0.01), and the DETECT algorithm (p=0.000017) between SSc experts and non-SSc experts.
Conclusions: Our findings reflect real-world screening practices in SSc patients, emphasising discrepancies which could stem from variations in clinical training, resource availability, or institutional protocols across healthcare settings.
{"title":"Interstitial Lung Disease and Pulmonary Arterial Hypertension Screening Practices in Systemic Sclerosis: Survey Insights of Rheumatologists in the Middle East and North Africa Region.","authors":"Rajaie Namas, Sarah Al Qassimi, Jawahir Alameri, Samar Al Emadi, Nelly Ziade, Ahlam Almarzooqi, Farida Al Balushi, Mohammed A Omair, Taha Qardaghi, Yasameen Abbas Humadi, Mohamed Alawlaqi, Hanan Al Rayes, Saadeya Naji, Fatima Haji, Fajer Altamimi, Mansour Alazmi, Hani Shatnawi, Waleed Hafiz, Deena Ahmed, Mariam Almansoori, Jamal Al Saleh, Hazem Rifaai, Mahdi Abusalameh, Zaki Abou Zahr, Hiba Khogali, Sehriban Diab, Maha Anbar, Adeeba Al Herz, Amal Elganzoury, Shaima Ewila, Basant Elnady, Wafa Madanat, Imad Uthman, Asia Mubashir, Mohamed Elarabi, Suzan Attar","doi":"10.31138/mjr.211224.alf","DOIUrl":"10.31138/mjr.211224.alf","url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are significant causes of morbidity and mortality in systemic sclerosis (SSc). Our objective was to determine screening practices for ILD and PAH in patients with SSc among rheumatologists in the Middle East and North Africa (MENA) region.</p><p><strong>Methods: </strong>An online questionnaire was distributed to rheumatologists across the MENA region. Participants were asked to estimate the proportion of SSc patients in their practice, indicate whether they screen for ILD and PAH, and specify how often they utilise screening modalities, including chest X-ray (CXR), high-resolution CT (HRCT), pulmonary function tests (PFTs), echocardiograms (ECHO), and the use of the DETECT algorithm. Data were analysed using descriptive statistics, with p-values ≤0.05 regarded as statistically significant.</p><p><strong>Results: </strong>394 respondents completed the questionnaire from 17 MENA countries. 389 (98.73%) reported screening for ILD, and 369 (93.65%) screened for PAH. 270 respondents performed screening at the time of SSc diagnosis (68.53%). Screening approaches for ILD included CXR (211, 53.55%), HRCT (321, 81.47%), and PFTs (299, 75.89%), while PAH screening included ECHO (346, 87.82%), and the DETECT algorithm (26.14%). Statistical differences were observed in the average number of SSc patients seen per year (p=0.0008), gender of respondents (p=0.02), current age (p=0.02), background training (p<0.00001), use of ECHO as PAH screening (p=0.01), and the DETECT algorithm (p=0.000017) between SSc experts and non-SSc experts.</p><p><strong>Conclusions: </strong>Our findings reflect real-world screening practices in SSc patients, emphasising discrepancies which could stem from variations in clinical training, resource availability, or institutional protocols across healthcare settings.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"392-402"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-18eCollection Date: 2025-09-01DOI: 10.31138/mjr.170225.iap
Monisha In, Nilanjana Dutta, Harshwardhan Patil, Mahabaleshwar Mamadapur, Veerendra Arakalavadi Guruswamy, Pavan Kumar M R
Background: Systemic autoimmune rheumatic diseases (SARDs) profoundly impact patients' quality of life (QoL) including sexual health, yet sexual dysfunction (SD) remains underrecognised in clinical care. Contributing factors include chronic pain, fatigue, joint stiffness, hormonal imbalances and psychological distress.
Objective: This review evaluates the prevalence, impact, and management of SD in patients with systemic autoimmune rheumatic diseases (SARDs), including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Sjögren's disease (SjD), and Systemic Sclerosis (SSc), as well as the related chronic condition Fibromyalgia Syndrome (FMS).
Methods: A systematic literature review was conducted using PubMed, Web of Science, and Scopus with relevant MeSH terms. Studies reporting SD in SARDs were included, with sexual function commonly assessed via the Female Sexual Function Index (FSFI) and International Index of Erectile Function (IIEF).
Results: SD prevalence ranged from 30% to 90%, varying by disease and gender. Up to 90% of women with SLE reported reduced desire and arousal. RA affected 30-70% of patients, with pain and depression as key drivers. In AS, erectile dysfunction affected 41-58% of men, influenced by age and disease duration. Over 56% of women with SjD experienced SD, often linked to vaginal dryness. SSc-induced fibrosis led to erectile dysfunction in 80% of men. FMS showed a 63% SD rate, associated with chronic pain and psychological burden.
Conclusion: SD is highly prevalent yet underaddressed in SARDs. A multidisciplinary approach combining pain management, psychological support, hormonal therapy, and patient education is essential.
背景:系统性自身免疫性风湿病(SARDs)深刻影响患者的生活质量(QoL),包括性健康,但性功能障碍(SD)在临床护理中仍未得到充分认识。诱发因素包括慢性疼痛、疲劳、关节僵硬、荷尔蒙失衡和心理困扰。目的:本综述评估系统性自身免疫性风湿性疾病(SARDs)患者SD的患病率、影响和管理,包括系统性红斑狼疮(SLE)、类风湿性关节炎(RA)、强直性脊柱炎(AS)、Sjögren病(SjD)和系统性硬化症(SSc),以及相关的慢性疾病纤维肌痛综合征(FMS)。方法:系统查阅PubMed、Web of Science、Scopus等相关MeSH术语的文献。研究报告了sard中的SD,性功能通常通过女性性功能指数(FSFI)和国际勃起功能指数(IIEF)进行评估。结果:SD患病率从30%到90%不等,因疾病和性别而异。高达90%的SLE女性报告性欲和性唤起降低。RA影响了30-70%的患者,疼痛和抑郁是主要驱动因素。在AS患者中,41-58%的男性存在勃起功能障碍,受年龄和疾病持续时间的影响。超过56%的女性患有性功能障碍,通常与阴道干燥有关。ssc诱导的纤维化导致80%的男性勃起功能障碍。FMS显示63%的SD率,与慢性疼痛和心理负担有关。结论:SD在SARDs中非常普遍,但未得到充分重视。结合疼痛管理、心理支持、激素治疗和患者教育的多学科方法是必不可少的。
{"title":"Sexual Dysfunction in Systemic Autoimmune Rheumatic Diseases: Prevalence, Impact, and Management Strategies.","authors":"Monisha In, Nilanjana Dutta, Harshwardhan Patil, Mahabaleshwar Mamadapur, Veerendra Arakalavadi Guruswamy, Pavan Kumar M R","doi":"10.31138/mjr.170225.iap","DOIUrl":"10.31138/mjr.170225.iap","url":null,"abstract":"<p><strong>Background: </strong>Systemic autoimmune rheumatic diseases (SARDs) profoundly impact patients' quality of life (QoL) including sexual health, yet sexual dysfunction (SD) remains underrecognised in clinical care. Contributing factors include chronic pain, fatigue, joint stiffness, hormonal imbalances and psychological distress.</p><p><strong>Objective: </strong>This review evaluates the prevalence, impact, and management of SD in patients with systemic autoimmune rheumatic diseases (SARDs), including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Sjögren's disease (SjD), and Systemic Sclerosis (SSc), as well as the related chronic condition Fibromyalgia Syndrome (FMS).</p><p><strong>Methods: </strong>A systematic literature review was conducted using PubMed, Web of Science, and Scopus with relevant MeSH terms. Studies reporting SD in SARDs were included, with sexual function commonly assessed via the Female Sexual Function Index (FSFI) and International Index of Erectile Function (IIEF).</p><p><strong>Results: </strong>SD prevalence ranged from 30% to 90%, varying by disease and gender. Up to 90% of women with SLE reported reduced desire and arousal. RA affected 30-70% of patients, with pain and depression as key drivers. In AS, erectile dysfunction affected 41-58% of men, influenced by age and disease duration. Over 56% of women with SjD experienced SD, often linked to vaginal dryness. SSc-induced fibrosis led to erectile dysfunction in 80% of men. FMS showed a 63% SD rate, associated with chronic pain and psychological burden.</p><p><strong>Conclusion: </strong>SD is highly prevalent yet underaddressed in SARDs. A multidisciplinary approach combining pain management, psychological support, hormonal therapy, and patient education is essential.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"466-478"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Lung involvement in paediatric rheumatic diseases significantly impacts morbidity and mortality. High-resolution computed tomography (HRCT) is a sensitive diagnostic tool but raises concerns about radiation exposure. Spirometry, a non-invasive and accessible test, is often used to assess pulmonary function, but its accuracy in detecting lung disease in newly diagnosed pediatric rheumatic conditions remains uncertain. This study evaluates spirometry's reliability, using HRCT as the reference standard.
Methods: Patients suspected of lung involvement due to respiratory symptoms or disease prevalence underwent HRCT and pulmonary assessment. A retrospective review of HRCT scans was conducted for 22 pediatric patients diagnosed with rheumatic disease (January 2021-December 2023), all of whom had pathological findings. HRCT was performed using a paired end-inspiratory and forced-expiratory protocol with 1-mm collimation. Radiological findings, including parenchymal opacities, ground-glass opacities, reticular patterns, honeycombing, parenchymal bands, bronchiectasis, peribronchial wall thickening, and air trapping, were assessed. Spirometric values-percent predicted Forced Expiratory Volume in 1 second (ppFEV1), Forced Vital Capacity (ppFVC), and FEV1/FVC ratio-were collected for patients with acceptable flow-volume curves.
Results: Seventeen of 22 patients (77.3%) had technically acceptable spirometry. Compared to HRCT, spirometry demonstrated a sensitivity of 29.4%.
Conclusion: Despite its excellent positive predictive value, spirometry's low sensitivity suggests it may miss early lung involvement in paediatric rheumatic diseases. HRCT remains the preferred diagnostic tool to ensure accurate detection and management, despite radiation concerns.
{"title":"Assessing Lung Involvement in Paediatric Rheumatic Diseases: A Retrospective Evaluation of the Limitations of Spirometry.","authors":"Spyridon Prountzos, Kyveli Chiotopoulou, Katerina Kourtesi, Evdoxia Sapountzi, Dafni Moriki, Elpiniki Kartsiouni, Euthymia Alexopoulou, Konstantinos Douros, Lampros Fotis","doi":"10.31138/mjr.020325.pae","DOIUrl":"10.31138/mjr.020325.pae","url":null,"abstract":"<p><strong>Objective: </strong>Lung involvement in paediatric rheumatic diseases significantly impacts morbidity and mortality. High-resolution computed tomography (HRCT) is a sensitive diagnostic tool but raises concerns about radiation exposure. Spirometry, a non-invasive and accessible test, is often used to assess pulmonary function, but its accuracy in detecting lung disease in newly diagnosed pediatric rheumatic conditions remains uncertain. This study evaluates spirometry's reliability, using HRCT as the reference standard.</p><p><strong>Methods: </strong>Patients suspected of lung involvement due to respiratory symptoms or disease prevalence underwent HRCT and pulmonary assessment. A retrospective review of HRCT scans was conducted for 22 pediatric patients diagnosed with rheumatic disease (January 2021-December 2023), all of whom had pathological findings. HRCT was performed using a paired end-inspiratory and forced-expiratory protocol with 1-mm collimation. Radiological findings, including parenchymal opacities, ground-glass opacities, reticular patterns, honeycombing, parenchymal bands, bronchiectasis, peribronchial wall thickening, and air trapping, were assessed. Spirometric values-percent predicted Forced Expiratory Volume in 1 second (ppFEV1), Forced Vital Capacity (ppFVC), and FEV1/FVC ratio-were collected for patients with acceptable flow-volume curves.</p><p><strong>Results: </strong>Seventeen of 22 patients (77.3%) had technically acceptable spirometry. Compared to HRCT, spirometry demonstrated a sensitivity of 29.4%.</p><p><strong>Conclusion: </strong>Despite its excellent positive predictive value, spirometry's low sensitivity suggests it may miss early lung involvement in paediatric rheumatic diseases. HRCT remains the preferred diagnostic tool to ensure accurate detection and management, despite radiation concerns.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"417-422"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-17eCollection Date: 2025-09-01DOI: 10.31138/mjr.110824.qcr
Fawzy M Abunejma, Rose Wazwaz, Romaisa Qawasma, Raghad Abu Dabaat, Oadi N Shrateh
Background: Despite Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy being widely acknowledged as a clinical entity and considered one of the most prevalent autoinflammatory diseases, there remains controversy surrounding its diagnostic criteria. Additionally, the epidemiology of the disease is largely unknown in Palestine. Therefore, the goal of this study is to enhance the understanding of PFAPA syndrome in Palestinian paediatric patients.
Methods: We carried out a retrospective cohort study that included 57 patients diagnosed with PFAPA at hospitals in Hebron, Palestine, specifically at Al-Ahli and the Palestinian Red Crescent Society (PRCS).
Results: The study revealed that PFAPA patients predominantly experienced fever (93.0%) and pharyngotonsillitis (100.0%), with significant associations noted between PFAPA and the presence of pharyngotonsillitis (p=0.006), adenitis (p=0.001), and periodicity. However, no significant associations were found between PFAPA and aphthous stomatitis, abdominal pain, or arthralgia. Patients with PFAPA were significantly less likely to experience diarrhoea (p=0.007) and chest pain (p=0.003). Treatment modalities included steroids (45.6%), tonsillectomy (57.9%), colchicine (91.2%), and antibiotics (56.1%).
Conclusions: This study offers important perception into the clinical characteristics, treatment outcomes, and epidemiology of PFAPA syndrome in Palestinian patients. The findings highlight fever and pharyngotonsillitis as predominant symptoms, along with significant associations observed with adenitis. Treatment approaches involving steroids, tonsillectomy, colchicine, and antibiotics were frequently utilised, with notable responses reported.
{"title":"Understanding PFAPA Syndrome in Palestine: A Retrospective Cohort Analysis of Epidemiological and Clinical Data.","authors":"Fawzy M Abunejma, Rose Wazwaz, Romaisa Qawasma, Raghad Abu Dabaat, Oadi N Shrateh","doi":"10.31138/mjr.110824.qcr","DOIUrl":"10.31138/mjr.110824.qcr","url":null,"abstract":"<p><strong>Background: </strong>Despite Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy being widely acknowledged as a clinical entity and considered one of the most prevalent autoinflammatory diseases, there remains controversy surrounding its diagnostic criteria. Additionally, the epidemiology of the disease is largely unknown in Palestine. Therefore, the goal of this study is to enhance the understanding of PFAPA syndrome in Palestinian paediatric patients.</p><p><strong>Methods: </strong>We carried out a retrospective cohort study that included 57 patients diagnosed with PFAPA at hospitals in Hebron, Palestine, specifically at Al-Ahli and the Palestinian Red Crescent Society (PRCS).</p><p><strong>Results: </strong>The study revealed that PFAPA patients predominantly experienced fever (93.0%) and pharyngotonsillitis (100.0%), with significant associations noted between PFAPA and the presence of pharyngotonsillitis (p=0.006), adenitis (p=0.001), and periodicity. However, no significant associations were found between PFAPA and aphthous stomatitis, abdominal pain, or arthralgia. Patients with PFAPA were significantly less likely to experience diarrhoea (p=0.007) and chest pain (p=0.003). Treatment modalities included steroids (45.6%), tonsillectomy (57.9%), colchicine (91.2%), and antibiotics (56.1%).</p><p><strong>Conclusions: </strong>This study offers important perception into the clinical characteristics, treatment outcomes, and epidemiology of PFAPA syndrome in Palestinian patients. The findings highlight fever and pharyngotonsillitis as predominant symptoms, along with significant associations observed with adenitis. Treatment approaches involving steroids, tonsillectomy, colchicine, and antibiotics were frequently utilised, with notable responses reported.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 3","pages":"387-391"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}